Annika Bergquist group
Our research is centered around autoimmune liver disease in particular primary sclerosing cholangitis (PSC) and bile duct cancer.
Primary sclerosing cholangitis, also known as PSC is an uncommon disease of the bile duct. PSC is characterized by inflammation of intra and extra hepatic bile ducts with close association to inflammatory bowel disease (IBD) and a high risk of development of biliary malignancy.
We focus our studies on the increased risk of malignancy in PSC in the colon and the liver. In detail, we search for and evaluate new diagnostic tools and early markers for disease progression, prognosis, malignancy, chemoprevention as well as treatment issues.
Our large cohort of patients of this rare disease provides good opportunities to perform epidemiological, clinical and translational research. We participate in the national study group for liver diseases (SWEHEP) and in the International PSC Study Group (IPSCSG) network. We also have a close collaboration with the Norwegian PSC Research Center.
Key words: Primary sclerosing cholangitis, cholangiocarcinoma, colorectal cancer, biomarkers
PiSCATIN – Simvastatin treatment for PSC – a randomized controlled trial
We are conducting a study with simvastatin 40 mg and placebo in patients with PSC. The hypothesis is based on a register study where PSC patients that were exposed to statins had a reduced risk (by half) for liver transplantation and death. The PiSCATIN study is planned to start in spring 2020. The study will include 700 patients treated for 5 years. All patients with a verified PSC diagnosis can participate. The primary outcome measures are transplantation, death, cholangiocarcinoma or variceal bleed. The study is registered at clinicaltrials.gov; NCT04133792.
New diagnostic and prognostic markers in PSC and cholangiocarcinoma
Researcher/project manager: Martin Cornillet-Jeannin
Cancer risk in PSC
Researcher: Aiva Lundberg Båve
A register based study on over all cancer risk in patients with PSC in Sweden, compared to controls from the general population.
Autoimmune and immune mediated disease in patients with PSC and their relatives compared to matched controls
Researcher: Aiva Lundberg Båve
Evaluating comorbidity with autoimmune disease and if autoimmune load can affect prognosis of PSC.
Skandinaviska PSC biobanken (The Scandinavian PSC Biobank)
Project manager: Lina Lindström Älgå
The PSC biobank is an international collaboration between Rikshospitalet in Oslo and Karolinska University Hospital. The aim is to include 1300 PSC patients and prospectively collect clinical and biological data, with the main goal to increase the knowledge on disease outcome in terms of cancer, death, and need for liver transplantation. The sampling includes clinical data in an eCRF as well as extensive biological sampling including serum, saliva, feces, and also bile, bile duct sampling, liver and colonic biopsies.
Aiva Lundberg BåveMD, PhD-student
Aiva was appointed specialist in Internal Medicine in 2014 and appointed specialist in Gastroenterology and Hepatology in 2016. Her clinical work is 50 % at the IBD and general gastroenterology clinic and 50 % at the hepatology clinic. Aiva was registered as a PhD student in May 2018. She was awarded top 5 abstract prize at UEGW 2019. Aiva is interested and engaged in educational questions. She is responsible for medical students on clinical rotation and in implementing Team Based Learning as a pedagogical tool for education of medical students. When not at work Aiva enjoys jogging, yoga, gardening, literature and theater.
Amanda KleinPhD, Research coordinator
Amanda has a Master of Science in Molecular Biology and her PhD-work focused on fat cell metabolism in lean and obese state. She did her postdoctoral training in a muscle physiology group developing a cell-based platform to screen for activators of PGC-1alpha1. Amanda works as a project coordinator in the group and is currently developing an eCRF for the PiSCATIN study. In her spare time Amanda enjoys running, yoga and vintage shopping.
Ann-Charlotte ElkanPhD, Research nurse
Ann-Charlotte received her PhD in rheumatology at Karolinska Institutet 2009. She completed postdoctoral training, at the Institute of Environmental Medicine (IMM), Karolinska Institutet, where she was studying the impact of life style factors in developing rheumatic diseases 2011. She was also the initiator/manager and coordinator for a lifestyle clinic at the Dept. of Rheumatology, Karolinska University Hospital, 2011-2012. Ann-Charlotte is coordinating and managing the research conducted at the Gastro Center, Karolinska University Hospital.
Erik von SethMD, PhD, postdoctoral researcher
Erik von Seth was appointed specialist in internal medicine in 2019 and now in training for specialization in gastroenterology and hepatology. He defended his thesis in 2018 which focused on ERCP and diagnostic methods of cholangiocarcinoma in PSC. Erik is investigating cancer risk, new methods to improve detection of malignant and pre-malignant lesions in the biliary tree and immunological aspects of bile duct inflammation in PSC.
Charlotte HedinMD, PhD, senior researcher
Dr Charlotte Hedin is a specialist in gastroenterology and internal medicine at the Karolinska University Hospital. She completed her PhD "Microbial, immunological, phenotypic and genetic markers of risk: aspects of Crohn’s disease that are shared by unaffected siblings" at King’s College London and Queen Mary University of London. In 2017 she was awarded a UEG Rising Star award for her research in IBD and in 2018 she was awarded the Karolina prize for “Exemplary patient flow and quality work” at the Karolinska Hospital. She holds a clinical post-doctorate from the Karolinska Hospital. She is a member of the Swedish Organisation for the study of IBD and is committee member for the European Crohn’s and Colitis Organisation. Charlotte’s research focusses on: 1. Extraintestinal inflammation in IBD inlcuding PSC, 2. Delineating pathogenic pathways in IBD through studying at-risk individuals (families of IBD patients) and 3. Defining the process of mucosal healing.
Lina Lindström ÄlgåMD, PhD, postdoctoral researcher
Lina is a MD specialized in gastroenterology. She finished her PhD in 2012 with main focus on IBD in PSC patients. She is currently training to be a transplant hepatologist at the department of transplantation and coordinating the PSC biobank. In her spare time she spends time with her children but dreams of writing more poetry.
Martin Cornillet-JeanninEngineer, PhD, Researcher Coordinator
Martin finished his PhD in 2014 focused on autoantibodies in Rheumatoid arthritis (Toulouse, France). He is now studying immunology of liver diseases, with a specific interest in the pathophysiology and prognosis of Primary Sclerosing Cholangitis (PSC). He likes cooking, practicing sports (karate, tennis, football) and is interested in art and music discovering.
Statin Use Is Associated With Improved Outcomes of Patients With Primary Sclerosing Cholangitis.
Stokkeland K, Höijer J, Bottai M, Söderberg-Löfdal K, Bergquist A
Clin. Gastroenterol. Hepatol. 2019 Aug;17(9):1860-1866.e1
Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities.
Goeppert B, Folseraas T, Roessler S, Kloor M, Volckmar AL, Endris V, et al
Hepatology 2020 Jan;():
Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis.
von Seth E, Ouchterlony H, Dobra K, Hjerpe A, Arnelo U, Haas S, et al
Liver Int. 2019 02;39(2):382-388
Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
Lindström L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A
Clin. Gastroenterol. Hepatol. 2013 Jul;11(7):841-6
Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis.
Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson A, Lindgren S, et al
Clin. Gastroenterol. Hepatol. 2008 Aug;6(8):939-43